Silo Pharma, Inc. announced a service agreement with Resyca BV to conduct a drug-device study on its microchip-based nasal spray system for SPC-15, an intranasal treatment for PTSD. This study aims to ...
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma (SILO), Inc. (“the Company”), a ...
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
A new economic impact study says South Plains College produces significant returns for the area's economy, students, businesses and taxpayers. The study reached three major conclusions. South Plains ...
Silo Pharma, Inc. has announced an agreement with Frontage Laboratories to conduct a 7-day safety and toxicology study on its lead drug, SPC-15, an intranasal treatment for PTSD. This study aims to ...
No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ...
SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback